Drug Pipeline

BBO-10203 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
1
Top Sponsors
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-03 NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer		 Primary endpoint(s) modified
2026-06-03 NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer		 Enrollment increased: 387 -> 665 participants
2026-06-03 NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer		 Trial arms changed: 14 -> 20
2026-06-03 NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer		 Trial sites expanded: 11 -> 17 locations
Active Studies by Phase
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT06625775 Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors Solid Tumor, Adult Recruiting
NCT06343402 Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Non-small Cell Lung Cancer Recruiting
NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer Non-Small Cell Lung Cancer Recruiting
Sponsors Running BBO-10203 Trials
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (3)
Disease Areas
Lung Cancer (3) Non-Small Cell Lung Cancer (NSCLC) (2) Colorectal Cancer (2) Breast Cancer (1) Pancreatic Cancer (1)
Get alerts when BBO-10203 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free